Return to Listing

10 result(s) for Multiple Myeloma

PI Name Protocol # Title
Emma Scott IRB00011097 A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Rachel Cook STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
Eva Medvedova STUDY00015608 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Emma Scott STUDY00015863 A Phase 1/2 Open label trial of SL-401 in combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Emma Scott STUDY00016649 Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Richard Maziarz STUDY00016982 A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Gabrielle Meyers STUDY00017140 GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Emma Scott STUDY00017199 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080